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Abstract
Background: In the search for more potent and safer tuberculosis vaccines, CAF01 was identified as a remarkable
formulation. Based on cationic liposomes and including a synthetic mycobacterial glycolipid as TLR-independent
immunomodulator, it induces strong and protective T helper-1 and T helper-17 adult murine responses to Ag85B-ESAT-6, a
major mycobacterial fusion protein. Here, we assessed whether these properties extend to early life and how CAF01
mediates its adjuvant properties in vivo.
Methods/Findings: Following adult or neonatal murine immunization, Ag85B-ESAT-6/CAF01 similarly reduced the post-
challenge bacterial growth of M. bovis BCG, whereas no protection was observed using Alum as control. This protection was
mediated by the induction of similarly strong Th1 and Th17 responses in both age groups. Multifunctional Th1 cells were
already elicited after a single vaccine dose and persisted at high levels for at least 6 months even after neonatal priming.
Unexpectedly, this potent adjuvanticity was not mediated by a massive targeting/activation of dendritic cells: in contrast,
very few DCs in the draining lymph nodes were bearing the labeled antigen/adjuvant. The increased expression of the CD40
and CD86 activation markers was restricted to the minute portion of adjuvant-bearing DCs. However, vaccine-associated
activated DCs were recovered several days after immunization.
Conclusion: The potent adult and neonatal adjuvanticity of CAF01 is associated in vivo with an exquisite but prolonged DC
uptake and activation, fulfilling the preclinical requirements for novel tuberculosis vaccines to be used in early life.
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and more efficacious vaccines against tuberculosis [1–4]. Despite
the lack of reliable biomarkers of protective immunity against M.
tuberculosis (Mtb), it is currently considered that these vaccines should
elicit anti-mycobacterial CD4
+ effector T cells producing type 1
cytokines, as highlighted by the severity of mycobacterial infections
when interleukin (IL)-12/interferon (IFN)-c [5,6] or tumor necrosis
factor (TNF)-a [7] responses are impaired. An important protective
role for T-helper 17 (Th17) cells is also suspected in the recruitment
of Th1 cells to the lung [8,9].
Exposure to Mtb may occur very early in life and infections with
Mtb are frequently severe in infants and young children whose
immature immune system fails to limit bacterial spread [10]. A
cornerstone of the global tuberculosis control program is thus to
immunize with Bacillus Calmette Guerin (BCG) soon after birth in
areas of high tuberculosis incidence. BCG vaccination is currently
quite effective (approximately 80%) in protecting human infants
from disseminated forms of disease including meningitis and
miliary TB [11]. It induces adult-like IFN-c responses [12,13],
probably as a result of prolonged replication and potent dendritic
cells (DC) activation and BCG-induced T cells express a vast array
of cytokine and phenotypic profiles [14,15]. However, BCG has
been unreliable as a vaccine to prevent the pulmonary form of TB.
In addition, it may lead to severe disseminated BCGitis in HIV-1
infected children such that WHO now officially recommends that
HIV-1 infected infants not to be immunized with BCG [16]. As
areas of high tuberculosis and HIV-1 prevalence partly overlap,
novel tuberculosis vaccines should induce potent and sustained
anti-mycobacterial responses early in life, while preferably using
non-replicating vaccines to avoid safety issues in neonates and
immunodeficient patients. Unfortunately, the Th1 response
capacity of human neonates is limited (reviewed in [17]) and
whether adult levels of Th17 effector cells may be elicited in early
human life is yet unknown. Thus, whether novel subunit
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5771tuberculosis vaccine candidates will eventually prove effective in
infants is difficult to predict.
Although there is ample evidence that mice may not be reliably
used to predict human vaccine efficacy [18], the main stages of
immune maturation are sufficiently well conserved between
humans and mice for specific neonatal animal models to
reproduce infant B and T cell response patterns [19–22]. We
and others have reported that the limitations of neonatal T cell
responses can be overcome by some specific vaccines and/or
through potent DC activation signals [12,23,24]. However,
aluminium salts, the only adjuvants currently licensed for use in
infants, exacerbate the Th2-like profile of neonatal responses
[25,26]. We recently reported that the novel IC31H adjuvant
elicits adult-like multifunctional neonatal CD4
+ T cells against a
fusion protein of two major tuberculosis antigens (Ag85B and
ESAT-6) [27]. IC31H contains a KLK peptide and a non-CpG
oligonucleotide mediating DC activation in a toll-like receptor
(TLR)-9 dependent manner [28,29]. However, human neonatal
DC respond poorly to TLR-9 signals [30,31] and whether IC31H
will be effective in early life is yet unknown.
Efforts to develop novel formulations have identified CAF01
(previously referred to as DDA-TDB or Lipovac) as another
promising adjuvant. CAF01 is based on cationic liposomes formed
by quaternary ammonium lipid N,N9-dimethyl-N,N9-dioctadecy-
lammonium (DDA) incorporating the synthetic mycobacterial
immunomodulator a,a9-trehalose 6,69-dibeheneate (TDB) [32–
34]. Compared to a panel of commercially available adjuvants,
CAF01 was particularly effective in generating strong Th-1 and
Th-17 T cell responses as well as strong antibody responses [33–
35]. Strong immunogenicity and protective efficacy of Ag85B-
ESAT-6 and CAF01, which will soon enter into a Phase I clinical
trial, was demonstrated in mice, guinea pigs and monkeys [34,36–
38]. DDA has been reported to increase antigen uptake and
presentation in vitro by bone-marrow derived DC [39], and TDB
elicits a potent activation of innate immunity including macro-
phages and DCs. Remarkably, this TDB-induced activation is
TLR-independent and mediated by the Syk-Card9-Bcl10-Mal-
t1signaling pathway [35]. One hypothesis was that the strong
potency of CAF01 was mediated by a massive targeting/activation
of DCs. Ag85B-ESAT-6/CAF01 thus provided a unique oppor-
tunity to test this hypothesis and to assess the adjuvanticity of
cationic based liposomes and the function of the Syk-Card9-NFkB
signalization pathway in early life.
Results
Protective efficacy of neonatal immunization against
mycobacterial infection
C57BL/6 mice were primed at 1 week of age (i.e. at the stage of
immune maturation that most closely reflect that of human
neonates [19]) or as adult controls with Ag85B-ESAT-6 (5 mg)
formulated in CAF01 or Alum (aluminum hydroxide: negative
control). Neonatal weight gain, a sensitive method of monitoring
neonatal reactogenicity, was normal in each group and local
reactions were not detected (data not shown). Mice were boosted 3
weeks later and challenged i.v. with Mycobacterium bovis BCG six
weeks after boosting, to investigate whether neonatal and adult
immunization would confer similar or distinct protection against a
model mycobacterial infection. Ag85B-ESAT-6/Alum did not
confer any protective efficacy, the number of CFU in spleen
(Fig. 1A) and lungs (Fig. 1B) being as high as in control mice. In
contrast, significantly lower bacterial counts were recovered from
mice immunized with Ag85B-ESAT-6 in CAF01 either as adults
or as neonates (Figure 1). Injection of CAF01 alone does afford
any protection against mycobacterial infection. [34]. Thus,
Ag85B-ESAT-6/CAF01 was selected for the further evaluation
of its immunogenicity and DC targeting/activation capacities.
Induction of adult-like multifunctional neonatal CD4
+
Th1 cells
Following neonatal immunization, Ag85B-ESAT-6/Alum elicits
weaker IFN-c and stronger IL-5 responses in neonates than in
adults, a Th2-preferential pattern characteristic of neonatal
vaccine responses (Fig. 2A and [27]). In contrast, a mirror pattern
consisting of similarly high IFN-c and modest IL-5 responses was
induced by Ag85B-ESAT-6/CAF01 in adults and neonates. The
induction of adult-like neonatal responses was confirmed by a
similar frequency of IFN-c and TNF-a producing cells in both age
groups, both early (6 weeks) and late (6 months) after boosting
(Fig. 2 B). These similarities extend to IL-2 and also to IL-17-
producing cells (Table 1 and data not shown). Cytokines (IFN-c,
TNF-a, IL2 and IL-17) producing cells were not detected in
splenocytes from H1/CAF01 immunized mice restimulated with
medium only, nor in stimulated and unstimulated splenocytes
from naı ¨ve mice or mice injected with only H1 or CAF01 (Fig. 2
and data not shown). The adult-like responses did not result from
the postnatal maturation of the immune system, as adult-like Th1
responses were already elicited after a single neonatal Ag85B-
ESAT-6/CAF01 immunization (Table 1). In accordance with
results in adults [33], Ag-specific CD8
+ T cells were not detected,
indicating that the protective efficacy of Ag85B-ESAT-6/CAF01
is associated with the induction of Th1 and Th17 CD4
+ T cells.
To further delineate the functionality of Ag85B-ESAT-6 specific
CD4
+ T cells elicited in early life, their co-production of IFN-c,
TNF-a and IL-2 was assessed by flow cytometry. Six weeks after
boosting, IFN-c, TNF-a and IL-2 were produced by CD44
hi
activated/memory CD4
+ T cells (not shown). Combination gating
to determine the cytokine production of single T cells indicated a
similar pattern whether mice were immunized with Ag85B-ESAT-
6/CAF01 in adult or early life (Fig. 3). Most cytokine
+ T cells
produced TNF-a/IL-2, often with IFN-c. Remarkably, this
multicytokine pattern was similar early (6 weeks) and late (6
months) after immunization. Thus, neonatal immunization with
Ag85B-ESAT-6 in CAF01 elicits adult-like multifunctional CD4
+
Th1-associated and Th17 responses that are significantly different
from the Th2-biased neonatal responses induced with Alum.
In vivo targeting and activation of neonatal and adult
dendritic cells
We next asked whether the remarkably potent induction of
adult-like Th1 and Th17 neonatal responses by Ag85B-ESAT-6/
CAF01 resulted from the in vivo targeting and activation of a large
number of DCs. The antigen and adjuvant were separately labeled
with fluorochromes to track antigen (Ag
+) and/or adjuvant (Adj
+)
DC in the draining lymph nodes (LN) after injection of Ag85B-
ESAT-6 in CAF01 (Fig. 4A and B), as similarly preformed in [40].
Twenty-four hours after adult immunization, cells were detected in
the draining LN associated with the fluorochrome-labeled
formulation. Adj
+ LN cells were mostly (84.264.8%) in the
CD11c
+ DC population, (Fig. 4A). Two populations were
detected: Ag
+Adj
+ (52.6614.0% of the total Adj+ DC) and
Ag
2Adj
+ cells (Fig. 4B). These Adj
+ DC were CD205
+ CD8
2, the
phenotype of periphery-derived DC [41] (data not show). Both the
proportion of total DCs (0.0960.04%) and the number (5236254)
of DCs per mouse that were Ag
+Adj
+ were low (Fig. 4C and D),
indicating that CAF01 adjuvanticity was not mediated through an
extensive DC targeting. A similar pattern was observed in
CAF01 in Adults and Neonates
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+ LN cells were
also mostly (71.269.8%) observed in the CD11c
+ DC population.
Among Adj
+ DCs, fewer cells were Ag
+ and Adj
+ DCs
(28.668.6% vs 52.6614.0%) in neonates than in adults. Despite
a higher proportion of Ag
+Adj
+ DCs in the total neonatal DC
population (0.1860.06%), this translated into even lower numbers
(1516119) of Ag
+Adj
+ DCs per 1-week-old mouse (Fig. 4) as a
result of differences in organ cellularity.
We postulated that such an exquisite DC targeting pattern





+ DCs in the draining LN at
various time points following Ag85B-ESAT-6/CAF01 immuniza-
tion. Neither Ag
+ nor Adj
+ DCs were identified 4 hours p.i.,
indicating that the formulation is retained efficiently at the
injection site (Fig. 5). In adults, vaccine-labeled cells were first
observed on Day 1, increased until Day 5 after immunization and
were not visualized any more on Day 21. The migration kinetics




+ DCs and in both age
groups (Fig. 5). Remarkably, there were very few vaccine-
associated DCs (100–1000 Ag
+Adj
+ DCs and 200–5000 Ag
2Adj
+
DCs) at any time point assessed (Fig. 5).
The apparent discrepancy between the induction of strong
Th1/Th17 responses and the paucity of Ag
+Adj
+ DCs in the
draining LN prompted us to define the activation pattern elicited
Figure 1. Ag85B-ESAT-6/CAF01 protects neonates and adults from mycobacterial infection. Immunized neonatal and adult mice were
challenged with Mycobacterium bovis BCG i.v. The CFU in spleen (A) and lung (B) (mean and SD, 6–8/group) were determined four weeks later, and is
representative of 2 independent experiments. *, p,0.05, differences between CAF01 and Alum or control were significant.
doi:10.1371/journal.pone.0005771.g001
CAF01 in Adults and Neonates
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CD86 co-stimulation molecules on all LN DCs indicated that
CAF01 only activated Adj
+ DCs (Fig. 6), without detectable
extension to bystander DCs. DC activation was phenotypically
similar in neonates and in adults. A classical DC activation marker
of Th1-triggering responses, IL-12p40 expression, was not
detected in any sample (not shown). Thus, the strong immuno-
genicity of Ag85B-ESAT-6/CAF01 in both adults and neonates is
not supported by a massive DC targeting and activation pattern
but in contrast by an exquisitely focused in vivo DC activation
pattern sustained during at least several days.
Discussion
Specific requirements have to be met for subunit vaccines to
elicit potent Th1 CD4
+ T cell responses, and these are even more
stringent in early life given the preferential induction of Th2-
biased CD4
+ T cell neonatal responses by conventional vaccines
[17,42]. We show here that the novel adjuvant formulation
CAF01 meets these requirements through the sustained targeting
of a very small number of DCs and their activation through an IL-
12 independent pathway.
The strong protective efficacy of Ag85B-ESAT-6/CAF01
against mycobacterial challenge [36–38,43] and its capacity to
induce potent Th1 and Th17 responses suggested that CAF01
mediated its adjuvanticity through a most efficient targeting and
activation of dendritic cells, the key regulators of T- and B-cell
immunity. Indeed, numerous vaccination strategies have shown
that enhancing DC targeting in vivo was required for potent CD4
+
and/or CD8
+ T cell responses [44]. However, protective
multifunctional Th1 and Th17 cells were elicited after 1 or 2
administrations of a formulation found to only label a minute DC
population. Indeed, the number of vaccine-associated cells in the
draining lymph nodes remained low (a few hundred DCs). We
cannot formally exclude that the fluorochrome intensity of the
labeled antigen and adjuvant in the in vivo setting may not reveal
all the labeled cell population. However, the hypothesis that a
successful vaccine requires general immune activation is not
supported by the fact that upregulation of co-stimulation
molecules is restricted to Adj
+ DCs (Fig. 6 and data not shown).
We recently reported that potent Th1 responses to Ag85B-ESAT-
6 may be elicited by the exquisite targeting/activation of a minute
proportion of DCs following the use of another adjuvant formulation,
IC31H [27,40]. IC31H contains a KLK peptide and a non-CpG
oligonucleotide which precipitate with antigen at the site of injection
[28]. Following immunization, fewer than 3000 vaccine-associated
cells per mice were retrieved from the draining LN, including 1500–
2000 Adj
+ (IC31H
+) DCs and 500 Ag
+Adj
+ DCs. This is remarkably
similar to the pattern elicited by Ag85B-ESAT-6/CAF01, which
r e s u l t e di n t ot h es a m en u m b e ro fA g
+Adj
+ LN DCs at 24 h after
immunization (Fig. 4). We wondered whether this pattern resulted
from limitations of lymphatic entry [45] or migration capacities of
peripheral DCs [46]. However, immunizations with other lipid-based
formulations resulted in 100-fold higher numbers of vaccine-
associated LN DCs (manuscript in preparation). Thus, the exquisite
targeting of a small number of DCs is an intrinsic property shared by
both IC31H and CAF01, despite major biochemical differences.
Another similarity between these two potent novel adjuvants is that
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Ex vivo intracellular cytokine staining




Neonates Adult p value
c Neonates Adult p value
2 doses
IFN-c 738657 7896255 ISC/10
6 splenocytes NS 1.160.3 1.860.5 NS
IL-2 9.661.5 12.862.4 U/ml NS 4.661.3 5.360.7 NS
TNF-a 0.960.1 0.960.2 ng/ml NS 5.261.4 6.160.7 NS
IL-17 30.563.5 22.462.4 ng/ml NS ND
d ND
1 dose
IFN-c 13.561.6 10.463.2 ng/ml NS ND ND
IL-5 0.560.2 0.660.2 ng/ml NS ND ND
aIFN-c secreting cells (ISC)/10
6 splenocytes were determined after 48 hr of culture with antigen and IL-2 (bioassay), TNF-a, IL-17, IFN-c and IL-5 (ELISA) after 72 hr of
culture with antigen. Cytokine production by unstimulated splenocytes from mice immunized with Ag85B-ESAT-6/CAF01 and antigen stimulated/unstimulated
splenocytes from mice immunized with Ag85B-ESAT-6 alone or CAF01 alone was below the limit of detection.
bFollowing 6 hr culture with antigen and co-stimulation (CD28/CD49d), percent of cytokine-producing cells determined by flow cytometry. Unstimulated splenocytes




Figure 2. Ag85B-ESAT-6/CAF01 induces sustained adult-like Th1 cell responses in neonates. (A–B). Three weeks after the second
immunization, splenocytes from neonatal and adult immunized mice were restimulated with antigen for 3 days. The production of IL-5 (A) and IFN-c
(B) was measured by ELISA. Cytokine production by unstimulated splenocytes was below the limit of detection. (C–D). Six weeks or 6 months after
boosting, Ag85B-ESAT-6 specific IFN-c (C) and TNF-a (D) producing cells were quantified by ICS. *, p,0.05 signifies differences between neonates and
adult mice. Data is represented by the mean and SD of groups of at least 6 individual mice, and is representative of 2–3 independent experiments.
doi:10.1371/journal.pone.0005771.g002
CAF01 in Adults and Neonates
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migration/activation of peripheral DCs from the injection site. The
duration of this phenomenon is difficult to estimate: vaccine-
associated cells were not retrieved from the draining LN on Day 21
after injection, which could be due to the detection limits of the
method or the completion of Ag
+/Adj
+ DC migration. Indeed, a
remarkable property of CAF01 is to elicit sustained CD4
+ Th1
responses: the proportion of antigen-specific CD4
+CD44
hi IFN-c or
TNF-a producing cells was similar 6 weeks and 6 months after
immunization (Fig. 2). Adoptive transfer experiments are thus
ongoing to address the hypothesis of prolonged DC recruitment at
the injection site.
The CAF01 and IC31H formulations also rely on distinct
immunomodulators: IC31H contains a non-CpG oligonucleotide
that mediate its signaling through TLR-9 and IL-12 [28], whereas
the TDB glycolipids of CAF01 activate the Syk-Card9-Bcl10-
Malt1 signaling pathway [35]. A peculiarity of this pathway is that
it does not only activate Th1 but also a strong Th17 response,
which could play an important role in recruiting effector cells into
the lungs at time of infection [8,9]. This provided us with a unique
opportunity to probe the function of the Syk-Card9-Bcl10-Malt1
signaling pathway in early life. The adult-like protection against a
mycobacterial challenge mediated by CD4
+ T cells, and the
induction of adult-like neonatal Th1 and Th17 cells after 2 or even
a single neonatal injection demonstrate that the activation of this
pathway is indeed functional early in life (Table 1). Should TDB
similarly effectively activate human neonatal DCs, in whom TLR-
mediated signaling is often poorly effective [30,31], this would
identify the CAF01 formulation as a most promising adjuvant for
vaccines against early life pathogens.
Figure 3. Ag85B-ESAT-6/CAF01 stimulates production of multifunctional CD4
+ T cells in neonates and adults. The expression of IFN-c,
IL-2 and TNF-a was determined by ICS on splenocytes from neonatal and adult mice, 6 weeks and 6 months post-boost. Cytokine production was
only detected in CD4
+ T cells from Ag/CAF01-immunized mice stimulated with antigen. The concurrent expression of IFN-c, IL-2 and TNF-a is
represented as pie graphs of cytokine expression by CD4
+ CD44
+ T cells of individual mice, and is representative of 2 independent experiments.
doi:10.1371/journal.pone.0005771.g003
CAF01 in Adults and Neonates
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Mice
Specific pathogen-free C57BL/6 mice (7 days of age (1-week-
old, neonates) or 8–12 weeks old (adult), Charles River) were bred
and kept under specific pathogen-free conditions in the university
zootechnology unit. Mice were immunized at the base of the neck
using the subcutaneous (s.c.) route. For analyses of in vivo DC
activation, the axial, brachial and auricular lymph nodes were
harvested. Manipulations were conducted according to Swiss and
European guidelines and experiments approved by the Geneva
Veterinary Office.
Antigen, Adjuvants and immunization
Recombinant Ag85B-ESAT-6 was prepared as described [50]
and coupled with AlexaFluor 647 (Invitrogen, Basel, Switzerland).
Dimethyldioctadecylammonium (DDA) bromide and a,a9-treha-
lose 6,69-dibehenate (TDB) were purchased from Avanti Polar
Lipids (Alabaster, AL) and the stable formulation designated
CAF01 prepared by the lipid film hydration method as described
[33]. To visualize CAF01, NBD-DPPE (1,2-Dipalmitoyl-sn-
Glycero-3-Phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-
4-yl) : Avanti Polar Lipids, Alabaster, AL) was incorporated (4.7%
w/w) during liposome preparation. Vaccines were formulated by
absorbing antigens (5 or 15 mg) with CAF01 or Al(OH)3 (Alum,
1 mg, gift of Novartis Vaccines and Diagnostics, Siena, Italy).
Buffer was used for control immunization. The addition of the
fluorochrome did not affect the immunogenicity of the formulation
(data not shown).
Determination of T cell responses
Splenocytes were cultured with Ag85B-ESAT-6 (5 mg/ml) or
medium alone. For determination of cytokine by ELISA or
bioassay, supernatants collected after 72 h for quantification by
Figure 4. Targeting of Ag85B-ESAT-6 and CAF01 in neonatal and adult DC of the draining LN. Twenty-four hours after immunization, (A)
the percentage of CAF01-NBD
+ CD11c
+ cells compared to all cells bearing the adjuvant in the draining LN was determined. In a representative dot
plot of an adult mouse, the percent of cells in quadrants is shown. (B) The percent of Ag85-ESAT-6
+ CAF01
+ DC amongst all CAF01
+ DC was
determined. In a representative histogram from an adult mouse, the presence of Ag85-ESAT-6-FITC in CAF01
+ DC (thick line) was calculated using
total DC as the control histogram (dotted line). The percent (C) and number (D) of Ag85-ESAT-6
+ CAF01
+ DC was calculated. The data are expressed as
mean and SD of groups of at least 4 individual mice, and is representative of 4 independent experiments. *, p,0.05 signifies differences between
neonatal and adult mice.
doi:10.1371/journal.pone.0005771.g004
CAF01 in Adults and Neonates
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Diego, CA), IL-17 (R&D Systems, Abingdon, UK) and by
bioassay IL-2 [51]. Under these conditions, blocking studies with
antibodies against CD4 (clone GK1.5) and CD8 (clone H35-17.2)
were undertaken. The antigen-specific IFN-c-secreting T cells
were quantified by ELISPOT, using Ag85B-ESAT-6 (2 mg/ml) or
media alone for 48 h [52]. Cytokine expression (IFN-c, TNF-a,
IL2) and multi-functional T cell patterns following 6 hour antigen
stimulation (5 mg/ml) of splenocytes were determined by intracel-
lular staining (ICS), as previously described [27].
Dendritic cell preparation, cell staining and flow
cytometry
CD11c
+ DC from draining LN were prepared by magnetic
selection (Miltenyi Biotec, Bergisch-Gladbach, Germany) as
described [27,40]. Cells were pre-incubated with rat anti-CD16/
32 mAb (2.4G2 clone), then stained with conjugated antibodies
against CD11c (HL3 clone), CD11b (M1/70 clone), CD8a (53-6.7
clone), isotype controls (BD Pharmingen), CD86 (GL1 clone)
(Biosource International, Camarillo CA), CD11c (N418 clone),
CD40 (FGK45 clone), MHC class II (M5/114.15.2 clone), CD205
(NLDC-145 clone) (produced in house). Cells were further stained
with streptavidin-PE or streptavidin-PECy7 (BD Pharmingen).
Each sample was acquired on the FACSCalibur or FACSAria
cytometers and data were analyzed using CellQuest Software (BD
Biosciences) or FlowJo Software (Tree Star, Ashland, OR).
Mycobacterial challenge
Six weeks after boost, mice were infected i.v with 10
7 CFU of
Mycobacterium bovis BCG Danish 1331. Four weeks p.i., mice were
sacrificed and spleens and lungs homogenized for bacterial
enumeration. Individual organs were plated in serial dilutions
onto Middlebrook 7H11 agar and incubated for 3 weeks at 37uC
prior to counting the number of CFU.
Figure 5. Kinetics of Ag85B-ESAT-6 and CAF01 labeled DC in the draining LN of adults and neonates. At various time points after
immunization, the number of Ag85-ESAT-6
+ CAF01
+ DC and Ag85-ESAT-6
2 CAF01
+ DC was calculated. The data are expressed as mean and SD of
groups of at least 4 individual mice. *, p,0.05 signifies differences between neonates and adult mice.
doi:10.1371/journal.pone.0005771.g005
CAF01 in Adults and Neonates
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Statistical analyses of the results obtained in various experi-
mental groups were performed with the Mann-Whitney U test or
ANOVA with Tukey test. Differences with probability values of
.0.05 were considered insignificant.
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